3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compounds for the management of CFTR protein mediated diseases
US10512636B2 · kind B2 · utility
3Cited by
5References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 27, 2016 |
| Grant date | Dec 24, 2019 |
| Priority date | — |
| Expiry date | May 27, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxa-diazole-5-carboxamide compound, salt, or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N-benzylidene-acetohydrazide compound is 3-(3,5-dibromo-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.